TOX4
Summary:
Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
---|---|---|---|---|---|
TOX high mobility group box family member 4 | MIM:614032 | Ensembl:ENSG00000092203 | HGNC:HGNC:20161 | PA162406753 | 14q11.2 |
GO terms in TOX4
Term Type | Evidence Type | GO Term ID | GO Des. |
---|---|---|---|
CC | IDA | GO:0000784 | nuclear chromosome, telomeric region |
CC | IDA | GO:0000785 | chromatin |
CC | IDA | GO:0072357 | PTW/PP1 phosphatase complex |
BP | IEA | GO:0006357 | regulation of transcription by RNA polymerase II |
MF | ISA | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
MF | ISM | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
MF | IEA | GO:0003677 | DNA binding |
MF | IPI | GO:0005515 | protein binding |
Gene expression in normal tissue: TOX4
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in TOX4
Database | Pathway ID | Pathway Des. |
---|
Gene-Drug: Aster Plot
Drug ID | Drug Name | Model Num. |
---|---|---|
iGMDRD446 | LY 2183240 | 4 |
iGMDRD193 | Fqi1 | 3 |
iGMDRD61 | Kinetin riboside | 1 |
iGMDRD163 | all trans Retinoic Acid | 3 |
iGMDRD901 | ELCPK | 2 |
iGMDRD634 | SCHEMBL2608041 | 2 |
iGMDRD154 | NSC23766 | 3 |
iGMDRD307 | Manumycin A | 3 |
iGMDRD151 | CHM-1 | 3 |
iGMDRD512 | nutlin 3 | 5 |
iGMDRD1008 | SR-II-138A | 3 |
iGMDRD560 | MK-2206 | 1 |
iGMDRD546 | BMS-754807 | 4 |
iGMDRD79 | Gemcitabine | 3 |
iGMDRD405 | PIK-75 | 3 |
iGMDRD100 | Zebularine | 6 |
iGMDRD399 | Selumetinib | 3 |
iGMDRD300 | Tozasertib | 2 |
iGMDRD690 | PRIMA-1MET | 3 |
iGMDRD147 | Prima-1 | 3 |
iGMDRD64 | Parbendazole | 3 |
iGMDRD103 | SN-38 | 3 |
iGMDRD513 | BML-259 | 3 |
iGMDRD121 | GMX1778 | 7 |
iGMDRD158 | NSC141540 | 6 |
iGMDRD137 | Indisulam | 6 |
iGMDRD138 | PX 12 | 3 |
iGMDRD260 | FQI-2 | 1 |
iGMDRD289 | Parthenolide | 3 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in TOX4